Trulicity latest diabetes drug to prove CV effect

Proving that diabetes drugs can reduce cardiovascular (CV) events is seen as vital by drugmakers in the space, and US pharma major Eli Lilly (NYSE: LLY) has responded to progress made by other treatments in this area by presenting data on Trulicity (dulaglutide).

Approved as a once-weekly injectable prescription medicine to improve blood sugar in adults with type 2 diabetes mellitus, the Lilly blockbuster significantly reduced major adverse cardiovascular events (MACE), meeting the primary efficacy objective in the REWIND trial.

Trulicity was compared to placebo when added to the standard of care.